Insulatard Penfill

Insulin Human, the active ingredient in Insulatard Penfill, is a insulin presented as a solution for injection (prefilled pen) for subcutaneous use. It treats type 1 and type 2 diabetes mellitus in patients who require basal insulin therapy.

GNH USA supplies Insulatard Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulatard Penfill provides long‑acting insulin to manage blood glucose in diabetes mellitus.

- Type 1 diabetes mellitus: supplies basal insulin to maintain fasting glucose levels. - Type 2 diabetes mellitus: complements oral agents or other insulin regimens for glycaemic control. - Diabetes requiring basal insulin therapy: delivers steady insulin action to reduce hyperglycaemia between meals and overnight.

Common Side Effects: - Hypoglycaemia: low blood sugar episodes, especially if dose is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: gradual increase in body weight with prolonged use. - Lipodystrophy: localized thickening or thinning of subcutaneous fat.

Serious or Rare Side Effects: - Severe hypoglycaemia: can lead to loss of consciousness or seizures. - Allergic reactions: including anaphylaxis, urticaria, or angioedema. - Insulin antibody formation: may alter insulin effectiveness. - Hypokalemia: low potassium levels, particularly with rapid glucose shifts. - Skin necrosis: rare necrotic lesions at injection sites.

Precautions for Insulatard Penfill include careful monitoring and individualized dosing. - Dose adjustment: tailor insulin dose based on regular blood glucose measurements. - Hypoglycaemia risk: educate patients to recognise and treat low glucose promptly. - Renal impairment: consider dose reduction in patients with reduced kidney function. - Pregnancy: use only when benefits outweigh potential risks to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulatard Penfill may interact with several drug classes.

Major Interactions (Avoid): - Beta‑blockers: can mask hypoglycaemia symptoms. - MAO inhibitors: may potentiate insulin’s glucose‑lowering effect. - Oral contraceptives: can increase insulin requirements. - Alcohol: may cause unpredictable glucose fluctuations.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose levels. - Corticosteroids: can increase insulin needs. - ACE inhibitors: may enhance insulin sensitivity, requiring dose review.